<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638585</url>
  </required_header>
  <id_info>
    <org_study_id>August 2</org_study_id>
    <secondary_id>2010-023426-20</secondary_id>
    <nct_id>NCT01638585</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia</brief_title>
  <acronym>August2</acronym>
  <official_title>Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized clinical trial (RCT) the investigators are trying to find out whether a
      low-dose therapy with daily short infusions of urokinase using 10 to 21 doses over a maximum
      of 30 days is capable of prolonging the survival time without major amputation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      August-2 is a trial embedded in the August-1 registry study. All patients enrolled in
      August-2 are also part of August-1, but there will be patients who are documented in the
      register, but will not take part in August-2. The investigators want to find out to which
      extent the patients in the registry are representative to the overall population suffering
      from this condition and how the therapeutic success of other therapy regimes can be
      described.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruition number was not reached
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of survival without major amputation in urokinase group compared to group with standard therapy</measure>
    <time_frame>within the FU of 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total mortality</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minor amputation</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of necessary revisions in case of minor amputation</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete healing of targeted lesion</measure>
    <time_frame>within the FU of 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new lesions on previously affected leg</measure>
    <time_frame>within the FU of 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy in dialysis patients</measure>
    <time_frame>within the FU of 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospital stay</measure>
    <time_frame>from baseline examination until first release (expected average of 2 weeks in general)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-hospitalization after dismissal following end of therapy with urokinase</measure>
    <time_frame>within the FU of 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necessity for parenteral therapy with vasoactive substances</measure>
    <time_frame>from baseline to end of 12 months FU</time_frame>
    <description>During the follow-up it will be documented wether the administration of parenterally applied vasoactive substances or thrombocyte aggregation inhibitors was necessary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>from baseline to end of 12 months FU</time_frame>
    <description>Any major cardiovascular events during the follow-up period. Duration, severity, outcome and causal relationship with urokinase therapy will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and type of bleeding events</measure>
    <time_frame>from randomization until day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and type of other adverse events</measure>
    <time_frame>from baseline to end of 12 months FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new lesions on the contralateral leg</measure>
    <time_frame>within the FU of 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>urokinase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving urokinase short infusions in addition to standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>urokinase</intervention_name>
    <description>daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization</description>
    <arm_group_label>urokinase</arm_group_label>
    <other_name>Urokinase HS medac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  angiopathic or angioneuropathic critical limb ischemia (at least Wagner-Armstrong
             stadium II)

          -  participation in the August-1 Register

          -  revascularization not possible or residual ischemia after revascularization

          -  persisting ulcerations despite antibiosis, adjustment of blood glucose levels and
             debridement

          -  expected further hospitalization for at least 3 weeks (pressure relief and antibiosis)

          -  fibrinogen &gt;= 4g/l

          -  signed informed consent

        Exclusion Criteria:

          -  life expectancy &lt; 1 year

          -  prior major amputation

          -  planned major amputation

          -  prior therapy of the current episode of diabetic foot syndrome with urokinase (except
             in cases of revascularization when the duration between the intervention and
             randomization must not exceed 7 days)

          -  mechanical heart valve substitute

          -  cerebral event with CT-detectable changes in the last 3 months

          -  non-remediated proliferation retinopathy

          -  uncontrolled hypertension (systolic &gt;180 mmg, diastolic &gt;100 mmHg)

          -  hemorrhagic diathesis (spontaneous quick &lt; 50%, spontaneous PTT &gt; 40 s, thrombocytes &lt;
             100 Gpt/l)

          -  gastrointestinal bleeding or ulcers in the last 4 weeks

          -  prior reverse bypass operation

          -  contraindications against therapy with urokinase acc. to the SMPc

          -  concurrent participation in another clinical trial

          -  insufficient compliance

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Schellong, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städt. KH Dresden-Friedrichstadt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Klinik</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. KH Königin Elisabeth Herzberge</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>14193</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld gGmbH</name>
      <address>
        <city>Bielefeld</city>
        <zip>33602</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein</name>
      <address>
        <city>Boppard</city>
        <zip>56154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus DD-Neustadt</name>
      <address>
        <city>Dresden</city>
        <zip>01129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum &quot;Carl Gustav Carus&quot; der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weißeritztal Kliniken GmbH</name>
      <address>
        <city>Freital</city>
        <zip>01705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Westklinikum</name>
      <address>
        <city>Hamburg</city>
        <zip>22559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Krankenhaus</name>
      <address>
        <city>Leisnig</city>
        <zip>04703</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Westfalen/Klinikum am Park</name>
      <address>
        <city>Lünen</city>
        <zip>44536</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Bürgerhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

